Pfiz­er's Paxlovid gets March FDA ad­vi­so­ry meet­ing to dis­cuss full ap­proval

Pfiz­er’s an­tivi­ral drug for Covid-19 is look­ing to inch clos­er to full FDA ap­proval, with an agency ad­vi­so­ry com­mit­tee sched­uled for March.

The meet­ing is go­ing to be held on March 16 from 9 a.m. to 5 p.m. EST, ac­cord­ing to a doc­u­ment in the fed­er­al reg­is­ter from the US De­part­ment of Health and Hu­man Ser­vices. The meet­ing will fo­cus on whether Paxlovid should be ap­proved to treat mild-to-mod­er­ate Covid-19 in adults who are at high risk for the virus’ pro­gres­sion to a se­vere case which can lead to hos­pi­tal­iza­tion or death.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER